RxDoctor Payments Data

Patrick Anderl, MD

Family Medicine · Bellevue, NENPI 1477968972

Payments from drug & device makers

$652in general payments, 2019–2025

Across 31 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$204
  • Amgen$141
  • Kiniksa Pharmaceuticals, Ltd.$107
  • Pfizer$56
  • Gilead$50
  • Boehringer Ingelheim$40
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$652100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$652 in reported general payments places this provider in the 50th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$106,400
Medicare patients
441
Services billed
1,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin50$51,236
EliquisApixaban39$33,750
XareltoRivaroxaban37$28,189
OzempicSemaglutide16$17,314
EntrestoSacubitril/Valsartan17$13,459
Breo ElliptaFluticasone/Vilanterol13$6,715
SymbicortBudesonide/Formoterol Fumarate13$4,268
Gabapentin99$2,907
Atorvastatin Calcium256$2,688
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,155
Albuterol Sulfate HfaAlbuterol Sulfate57$2,013
Levothyroxine Sodium178$1,854
Pantoprazole Sodium66$1,454
Omeprazole112$1,245
Metoprolol Succinate90$1,123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$40$51,23650 claims
PfizerEliquis$56$33,75039 claims
Johnson & JohnsonXarelto$18$28,18937 claims
NovartisEntresto$204$13,45917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Bellevue

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →